# Sutro Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sutro-biopharma

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.sutrobio.com/
- Total disclosed funding: $181M
- Latest round: Series E (Aug 8, 2018)
- Investors on record: 14

## About

Sutro Biopharma, Inc. is a US-based biotechnology company focused on developing innovative cancer therapies using advanced site-specific antibody-drug conjugates (ADCs) and biologics to enhance patient outcomes.Founded in 2003 and headquartered in South San Francisco, US, Sutro Biopharma, Inc. specializes in cancer therapeutics. The firm has raised a total of USD 126.00 mn through various funding rounds, with the latest being a Private Placement/Follow on raising USD 126.00 mn in December 2020. The company has executed 12 deals, with its most recent deal occurring on September 26, 2018. Bill Newell serves as the CEO.Sutro Biopharma, Inc. specializes in the discovery and development of innovative cancer therapeutics, primarily focusing on site-specific antibody-drug conjugates (ADCs) and other advanced biologics. The proprietary XpressCF® system enables rapid production of these therapeutics, targeting various cancers with high precision to enhance patient outcomes while minimizing off-target effects. The main clientele includes pharmaceutical companies and research institutions that utilize these specialized treatments in clinical trials and therapeutic applications, primarily marketed in North America and Europe.Sutro Biopharma generated revenue of USD 62.04 mn in the most recent year, 2024, with an EBITDA of USD -231.24 mn. Revenue is derived through collaborative partnerships and licensing agreements with pharmaceutical companies for the development of proprietary therapeutics, involving upfront payments, milestone payments, and royalty payments on future sales. Key products include advanced ADCs that target specific tumor markers, underpinning the company's B2B business model focused on oncology drug pipelines.Sutro Biopharma plans to leverage recent funding from its December 2020 round, which raised USD 126.00 mn, to advance the development of new products and expand into new markets. The company is working on innovative ADCs set for launch in upcoming quarters. Sutro aims to penetrate additional European markets and increase its presence in Asia by 2025. The funding will support R&D initiatives and facilitate partnerships for scaling operations in these regions.

## Funding rounds

- Series E, Aug 8, 2018, $54M — Alta Partners, Lilly Ventures, Skyline Ventures, SV Health Investors, Amgen Ventures, Tekla Capital Management, Surveyor Capital, Merck & Co., Inc., Bristol-Myers Squibb Company, Eventide Asset Management, Vida Ventures, Samsara BioCapital, Nexthera Capital
- Series E, May 24, 2018, $32M — Samsara BioCapital, Surveyor Capital
- Series D, Dec 11, 2013, $26M — Alta Partners, Lilly Ventures, Skyline Ventures, SV Health Investors, Amgen Ventures, Celgene
- Series C, Mar 28, 2012, $13M — Alta Partners, Lilly Ventures, Skyline Ventures, SV Health Investors, Amgen Ventures
- Series C, Nov 5, 2010, $19M — Alta Partners, Lilly Ventures, Skyline Ventures, SV Health Investors, Amgen Ventures
- Series B, Mar 30, 2009, $15M — Alta Partners, SV Health Investors
- Series B, Dec 10, 2007, $21M — Alta Partners, SV Health Investors
- Series A, Jun 1, 2006, $1M — SV Health Investors

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B, Series C, Series D, Series E
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series B, Series C, Series D, Series E
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series C, Series D, Series E
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series C, Series D, Series E
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series C, Series D, Series E
- Celgene — Series D
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series E
- Surveyor Capital — Series E
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series E
- Merck & Co., Inc. — Series E
- Bristol-Myers Squibb Company — Series E
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series E
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series E
- Nexthera Capital — Series E